These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 32379409)
1. Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec. Audrey-Bayan C; Trager MH; Gartrell-Corrado RD; Rizk EM; Pradhan J; Silverman AM; Lopez A; Marks DK; Niedt G; Geskin LJ; Saenger YM Melanoma Res; 2020 Aug; 30(4):410-415. PubMed ID: 32379409 [TBL] [Abstract][Full Text] [Related]
2. False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC). Mulder EEAP; Stahlie EHA; Verver D; Lemstra C; Been LB; Mooyaart AL; Brabander T; Vegt E; Verburg FA; van der Veldt AAM; Verhoef C; van Akkooi ACJ; Grünhagen DJ J Surg Oncol; 2021 Dec; 124(7):1161-1165. PubMed ID: 34235758 [TBL] [Abstract][Full Text] [Related]
3. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series. Sun L; Funchain P; Song JM; Rayman P; Tannenbaum C; Ko J; Mcnamara M; Marcela Diaz-Montero C; Gastman B J Immunother Cancer; 2018 May; 6(1):36. PubMed ID: 29764498 [TBL] [Abstract][Full Text] [Related]
5. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650 [TBL] [Abstract][Full Text] [Related]
6. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab. Afzal MZ; Shirai K J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044 [TBL] [Abstract][Full Text] [Related]
7. Retreatment with talimogene laherparepvec for advanced melanoma. Hu J; Masoud SJ; Ravichandran S; Beasley GM; Mosca PJ Immunotherapy; 2020 Nov; 12(16):1167-1172. PubMed ID: 32840157 [No Abstract] [Full Text] [Related]
8. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039 [TBL] [Abstract][Full Text] [Related]
9. Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells. Tijtgat J; De Munck J; Dufait I; Schwarze JK; Van Riet I; Franceschini L; Breckpot K; Aerts JL; Neyns B; Tuyaerts S Front Immunol; 2021; 12():733506. PubMed ID: 34777344 [TBL] [Abstract][Full Text] [Related]
10. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293 [TBL] [Abstract][Full Text] [Related]
11. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma. Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610 [TBL] [Abstract][Full Text] [Related]
12. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey. Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143 [TBL] [Abstract][Full Text] [Related]
13. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition. Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046 [TBL] [Abstract][Full Text] [Related]
14. Regression of mucosal melanoma following intralesional talimogene laherparepvec (T-VEC) injection in combination with immunotherapy. Drescher C; Drexler K; Hilber H; Schmidt B; Haferkamp S J Dtsch Dermatol Ges; 2019 Mar; 17(3):321-323. PubMed ID: 30698924 [No Abstract] [Full Text] [Related]
15. Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size. Masoud SJ; Hu JB; Beasley GM; Stewart JH; Mosca PJ Ann Surg Oncol; 2019 Dec; 26(13):4633-4641. PubMed ID: 31414290 [TBL] [Abstract][Full Text] [Related]